Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
Abroad (travel likely)Recruiting
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
CMIC Co., Ltd, Tokyo, Japan
Study leads
Bristol Myers Squibb
Study Director
Bristol-Myers Squibb